APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)

NCT03745716 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

154

Enrollment

INDUSTRY

Sponsor class

Conditions

MDS

Interventions

DRUG: APR-246 + azacitidine
DRUG: Azacitidine

Sponsor

Aprea Therapeutics